Kuangli Bio-Tech Holdings (6431) Fair Value & Analysis
Consumer Defensive · TW · Market cap 1.7B TWD
Fair value as of: Jul 21, 2026
From 3 valuation models · updated 20 days ago
Share price +7.4% over the past month.
Below-average quality, and screening another 13% overvalued on our models.
What matters now
- The model range is unusually wide (8.65 TWD to 25.59 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 10.60 TWD – 36.95 TWD · fair‑value band 8.65 TWD – 25.59 TWD · the 19.60 TWD price screens above the 17.07 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Kuangli Bio-Tech Holdings (6431) currently trades at 19.60 TWD, while our model-based Fair Value estimate is 17.07 TWD, implying the stock looks roughly 12.9% overvalued today. The Quality Score stands at 28/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Kuangli Bio-Tech Holdings generated revenue of 353M TWD at a net margin of -55.3%. Revenue declined 21.7% year over year. It earns a return on equity of -29.7%. Net debt stands at 278M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 8.65 TWD (bear case) to 25.59 TWD (bull case); at 19.60 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 32% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -13%, 6431 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Dividend Discount (14.98 TWD) versus Asset-Based (3.97 TWD). Highest evidence: Gordon GGM (70).
Notify me when 6431 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 28 · Market factors (momentum, volatility) 47
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Kuangli Bio-Tech Holdings Co., Ltd. manufactures and sells panels for cover lens used in various electronic products in Taiwan and China. The company's products are used in mobile phone, PDA, instrument panels, digital camera windows, medical equipment, etc.
Full company description
Kuangli Bio-Tech Holdings Co., Ltd. manufactures and sells panels for cover lens used in various electronic products in Taiwan and China. The company's products are used in mobile phone, PDA, instrument panels, digital camera windows, medical equipment, etc. It also engages in research and development, manufacturing, and sale of related biotech products, such as cosmetic, skin care, and health food products. The company was formerly known as Kuangli Photoelectric Technology Co., Ltd. Kuangli Bio-Tech Holdings Co., Ltd. was founded in 2012 and is based in Grand Cayman, Cayman Islands.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kuangli Bio-Tech Holdings reported revenue of 377M TWD in FY2025 versus 358M TWD in FY2021, a compound +1.3%/yr. Reported net income was −193M TWD in FY2025.
6431 screens 13% overvalued. Compare with The Procter & Gamble Company →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Kuangli Bio-Tech Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Kuangli Bio-Tech Holdings (6431) overvalued or undervalued?
What is the fair value of 6431?
What is the quality score of 6431?
What is the revenue of Kuangli Bio-Tech Holdings (6431)?
What is the net profit margin of 6431?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Kuangli Bio-Tech Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.